Recro Pharma Company Profile (NASDAQ:REPH)

About Recro Pharma (NASDAQ:REPH)

Recro Pharma logoRecro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:REPH
  • CUSIP: N/A
  • Web: www.recropharma.com
Capitalization:
  • Market Cap: $157.16 million
  • Outstanding Shares: 19,050,000
Average Prices:
  • 50 Day Moving Avg: $8.06
  • 200 Day Moving Avg: $7.80
  • 52 Week Range: $5.89 - $12.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $70.34 million
  • Price / Sales: 2.23
  • Book Value: $3.38 per share
  • Price / Book: 2.44
Profitability:
  • EBIDTA: ($9,470,000.00)
  • Net Margins: -13.34%
  • Return on Equity: -57.17%
  • Return on Assets: -15.22%
Debt:
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 4.35%
  • Quick Ratio: 3.48%
Misc:
  • Average Volume: 155,847 shs.
  • Beta: -0.62
  • Short Ratio: 3.48
 

Frequently Asked Questions for Recro Pharma (NASDAQ:REPH)

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.16. The firm earned $18.74 million during the quarter, compared to analysts' expectations of $15.58 million. Recro Pharma had a negative net margin of 13.34% and a negative return on equity of 57.17%. View Recro Pharma's Earnings History.

Where is Recro Pharma's stock going? Where will Recro Pharma's stock price be in 2017?

6 equities research analysts have issued 1-year price objectives for Recro Pharma's stock. Their predictions range from $11.00 to $21.00. On average, they expect Recro Pharma's stock price to reach $17.33 in the next twelve months. View Analyst Ratings for Recro Pharma.

Who are some of Recro Pharma's key competitors?

Who owns Recro Pharma stock?

Recro Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (16.27%), Stonepine Capital Management LLC (15.09%), STONEPINE CAPITAL MANAGEMENT, LLC (9.99%), LYTTON LAURENCE W (6.20%), Vanguard Group Inc. (2.94%) and Kingdon Capital Management L.L.C. (1.63%). Company insiders that own Recro Pharma stock include Alfred Altomari, Charles Garner, Donna Nichols, Geraldine Henwood, Healthcare Master Fun Broadfin, Karen Flynn, Randall Mack, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp, Stewart Mccallum, Stonepine Capital Management, and Winston J Churchill. View Institutional Ownership Trends for Recro Pharma.

Who sold Recro Pharma stock? Who is selling Recro Pharma stock?

Recro Pharma's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Granite Point Capital Management L.P., Essex Investment Management Co. LLC and Kingdon Capital Management L.L.C.. Company insiders that have sold Recro Pharma stock in the last year include Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Stonepine Capital Management,. View Insider Buying and Selling for Recro Pharma.

Who bought Recro Pharma stock? Who is buying Recro Pharma stock?

Recro Pharma's stock was bought by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., TFS Capital LLC, Renaissance Technologies LLC, Oxford Asset Management, Segantii Capital Management Ltd and Geode Capital Management LLC. Company insiders that have bought Recro Pharma stock in the last two years include Alfred Altomari, Charles Garner, Donna Nichols, Geraldine Henwood, Healthcare Master Fun Broadfin, Karen Flynn, Randall Mack and Stewart Mccallum. View Insider Buying and Selling for Recro Pharma.

How do I buy Recro Pharma stock?

Shares of Recro Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Recro Pharma stock cost?

One share of Recro Pharma stock can currently be purchased for approximately $8.25.

Analyst Ratings

Consensus Ratings for Recro Pharma (NASDAQ:REPH) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.33 (110.10% upside)

Analysts' Ratings History for Recro Pharma (NASDAQ:REPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017Roth CapitalSet Price TargetBuy$20.00HighView Rating Details
3/27/2017AegisReiterated RatingBuy$11.00LowView Rating Details
12/19/2016Piper Jaffray CompaniesInitiated CoverageOverweight$12.00N/AView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$19.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$21.00N/AView Rating Details
8/29/2016Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Recro Pharma (NASDAQ:REPH)
Earnings by Quarter for Recro Pharma (NASDAQ:REPH)
Earnings History by Quarter for Recro Pharma (NASDAQ:REPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.58)($0.42)$15.58 million$18.74 millionViewN/AView Earnings Details
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13$13.00 million$16.75 millionViewN/AView Earnings Details
11/13/2015Q3($0.20)($0.24)$16.54 millionViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Recro Pharma (NASDAQ:REPH)
2017 EPS Consensus Estimate: ($2.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.61)($0.61)($0.61)
Q4 20171($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Recro Pharma (NASDAQ:REPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Recro Pharma (NASDAQ:REPH)
Insider Ownership Percentage: 39.30%
Institutional Ownership Percentage: 53.23%
Insider Trades by Quarter for Recro Pharma (NASDAQ:REPH)
Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)
Insider Trades by Quarter for Recro Pharma (NASDAQ:REPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Stonepine Capital Management,Major ShareholderSell510,000$7.40$3,774,000.00View SEC Filing  
5/11/2017Stonepine Capital Management,Major ShareholderSell244,629$7.65$1,871,411.85View SEC Filing  
5/4/2017Stonepine Capital Management,Major ShareholderSell217,308$7.70$1,673,271.60View SEC Filing  
3/16/2017Scp Vitalife Partners Ii LpMajor ShareholderSell44,977$8.00$359,816.00View SEC Filing  
2/17/2017Scp Vitalife Partners Ii LpMajor ShareholderSell9,983$7.59$75,770.97View SEC Filing  
2/16/2017Scp Vitalife Partners (Israel)Major ShareholderSell4,030$7.89$31,796.70View SEC Filing  
12/16/2016Karen FlynnDirectorBuy800$6.71$5,368.00View SEC Filing  
12/15/2016Alfred AltomariDirectorBuy1,500$6.55$9,825.00View SEC Filing  
12/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy650,000$6.00$3,900,000.00View SEC Filing  
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.00View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.00View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.20View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.00View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Recro Pharma (NASDAQ:REPH)
Latest Headlines for Recro Pharma (NASDAQ:REPH)
Source:
DateHeadline
investorplace.com logoCumberland Pharmaceuticals, Inc. (CPIX) and Recro Pharma Inc (REPH) Lead 9 Notable Investor Filings - Investorplace.com
investorplace.com - May 24 at 9:48 AM
investorplace.com logoCumberland Pharmaceuticals, Inc. (CPIX) and Recro Pharma Inc (REPH) Lead 9 Notable Investor Filings
investorplace.com - May 22 at 10:31 AM
streetinsider.com logoForm 8-K Recro Pharma, Inc. For: May 18 - StreetInsider.com
www.streetinsider.com - May 21 at 12:03 AM
finance.yahoo.com logoRecro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
finance.yahoo.com - May 18 at 10:04 AM
benzinga.com logoExclusive: Recro Pharma CEO Talks Meloxicam Non-Opioid Product Ahead Of APS Annual Meeting
www.benzinga.com - May 17 at 7:27 PM
americanbankingnews.com logoZacks Investment Research Upgrades Recro Pharma Inc (REPH) to Buy
www.americanbankingnews.com - May 17 at 7:30 AM
globenewswire.com logoRecro Pharma to Present Phase III Bunionectomy Clinical Data for ... - GlobeNewswire (press release)
globenewswire.com - May 16 at 7:23 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Major Shareholder Stonepine Capital Management, Sells 510,000 Shares
www.americanbankingnews.com - May 15 at 7:10 PM
finance.yahoo.com logoRecro Pharma to Present Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
finance.yahoo.com - May 15 at 9:38 AM
americanbankingnews.com logoRecro Pharma Inc (REPH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 12 at 2:58 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - May 12 at 12:38 PM
americanbankingnews.com logoInsider Selling: Recro Pharma Inc (REPH) Major Shareholder Sells 244,629 Shares of Stock
www.americanbankingnews.com - May 11 at 10:14 PM
finance.yahoo.com logoRecro Pharma reports 1Q loss
finance.yahoo.com - May 11 at 7:58 PM
streetinsider.com logoRecro Pharma (REPH) Reports Top-Line Results from Phase III Safety Study of IV Meloxicam - StreetInsider.com
www.streetinsider.com - May 11 at 8:17 AM
globenewswire.com logoRecro Pharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 8:17 AM
finance.yahoo.com logoRecro Pharma Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 8:17 AM
streetinsider.com logoRecro Pharma (REPH) Reports Top-Line Results from Phase III Safety Study of IV Meloxicam
www.streetinsider.com - May 9 at 10:49 AM
finance.yahoo.com logoRecro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
finance.yahoo.com - May 9 at 10:49 AM
americanbankingnews.com logoRecro Pharma (REPH) Getting Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - May 5 at 11:45 PM
americanbankingnews.com logoStonepine Capital Management, Sells 217,308 Shares of Recro Pharma Inc (REPH) Stock
www.americanbankingnews.com - May 5 at 8:00 PM
americanbankingnews.com logo Brokerages Expect Recro Pharma Inc (REPH) to Announce -$0.60 EPS
www.americanbankingnews.com - May 1 at 7:44 PM
americanbankingnews.com logoRecro Pharma (REPH) Given Daily Media Sentiment Score of 0.31
www.americanbankingnews.com - May 1 at 5:08 PM
americanbankingnews.com logoRecro Pharma (REPH) Receives Coverage Optimism Rating of -0.10
www.americanbankingnews.com - April 26 at 1:44 PM
americanbankingnews.com logoRecro Pharma (REPH) Getting Somewhat Negative Media Coverage, Study Shows
www.americanbankingnews.com - April 23 at 11:03 AM
americanbankingnews.com logoRecro Pharma (REPH) Getting Somewhat Positive News Coverage, Study Shows
www.americanbankingnews.com - April 20 at 9:47 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 17 at 3:28 PM
americanbankingnews.com logoRecro Pharma (REPH) Getting Somewhat Favorable Press Coverage, Study Shows
www.americanbankingnews.com - April 16 at 1:49 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Short Interest Down 29.5% in March
www.americanbankingnews.com - April 13 at 4:50 PM
americanbankingnews.com logoRecro Pharma (REPH) Receiving Somewhat Critical Media Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 10:47 AM
americanbankingnews.com logo$15.58 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter
www.americanbankingnews.com - April 12 at 11:54 AM
americanbankingnews.com logo Brokerages Anticipate Recro Pharma Inc (REPH) Will Post Earnings of -$0.60 Per Share
www.americanbankingnews.com - April 10 at 1:00 PM
finance.yahoo.com logoETFs with exposure to Recro Pharma, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:52 PM
americanbankingnews.com logoRecro Pharma's (REPH) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - March 31 at 10:14 AM
finance.yahoo.com logoRecro Pharma to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 29 at 8:42 AM
americanbankingnews.com logoRecro Pharma's (REPH) "Buy" Rating Reaffirmed at Aegis
www.americanbankingnews.com - March 27 at 12:26 PM
seekingalpha.com logoRecro Pharma (REPH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 8:00 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 22 at 12:43 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 21 at 8:53 AM
finance.yahoo.com logoRecro Pharma to Present at the Oppenheimer 27th Annual Healthcare Conference - Yahoo Finance
finance.yahoo.com - March 16 at 8:15 AM
finance.yahoo.com logoRECRO PHARMA, INC. Financials
finance.yahoo.com - March 15 at 7:44 PM
americanbankingnews.com logoRecro Pharma Inc (REPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 11 at 12:43 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 7:31 PM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Stateme
biz.yahoo.com - March 7 at 9:29 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements
biz.yahoo.com - March 6 at 6:50 PM
finance.yahoo.com logoRecro Pharma Reports Year End 2016 Financial Results
finance.yahoo.com - March 6 at 6:50 PM
finance.yahoo.com logoRecro Pharma Appoints Bryan Reasons to Its Board of Directors
finance.yahoo.com - March 6 at 9:44 AM
globenewswire.com logoRecro Pharma to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 2 at 8:17 AM
feeds.benzinga.com logoRecro Pharma to Present at Upcoming Investor Conferences
feeds.benzinga.com - March 2 at 7:54 AM
finance.yahoo.com logoRecro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam
finance.yahoo.com - February 27 at 9:33 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 27 at 9:33 AM

Social

Chart

Recro Pharma (REPH) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff